Aldeyra Therapeutics Inc (ALDX) Stock AnalysisALDXStock AnalysisAldeyra Therapeutics Inc

Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering therapies designed to treat immune-mediated and metabolic diseases. The Company's approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Its product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX 248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Its late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. ADX 629 is in Phase II clinical trials for moderate alcohol-associated hepatitis and Sjogren-Larsson Syndrome. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Aldeyra Therapeutics is not a good buy right now. The current price is $1.485, which is significantly lower than the downgraded analyst price target of $2. Additionally, the stock has experienced a year-to-date change of -68.20%, indicating severe underperformance. The RSI is at 34.952, suggesting that the stock is oversold but may not recover soon due to the recent FDA rejection of its dry eye treatment, which has led to a 75% drop in stock value. The main risk is the company's negative net income, which was -$5,450,273 in Q2 2026, reflecting ongoing financial struggles that could hinder recovery efforts.

5 analysts cover ALDX: 5 rate it Buy, 0 Hold and 0 Sell. The average price target is 9.50.